Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BCL6 | P41182 | 3/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20749043 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1POLBFGFR4LMNA | |
| SCHEMBL19630089 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1POLBFGFR4LMNA | |
| SCHEMBL29740013 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1POLBFGFR4LMNA | |
| SCHEMBL29740112 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1POLBFGFR4LMNA | |
| SCHEMBL19629939 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1POLBFGFR4LMNA | |
| SCHEMBL20740396 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1POLBFGFR4LMNA | |
| SCHEMBL20740389 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1POLBFGFR4LMNA | |
| SCHEMBL21346353 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1POLBFGFR4LMNA | |
| SCHEMBL19866713 | 0.93 | MAPT (0.37) | KDM4EALDH1A1POLBFGFR4LMNA | |
| SCHEMBL19866714 | 0.93 | MAPT (0.37) | KDM4EALDH1A1POLBFGFR4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4053126-B1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | BROADENBIO CO LTD (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-12344611-B2 | Bridged cycloformylpyridine derivatives and uses thereof | BROADENBIO CO., LTD. (CN) | 2025-07-01 | — | — | US | disclosed |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | BROADENBIO CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| EP-4053126-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | Broadenbio Co., Ltd. (CN) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021083011-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | 北京伯汇生物技术有限公司 | 2021-05-06 | — | — | WO | disclosed |
| US-20190276451-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190276451-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| EP-3444250-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
| EP-3444250-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017198149-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | 江苏豪森药业集团有限公司 | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276451-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | FGFR4, FGFR1, FGFR2 | KDM4E 1217/4885ALDH1A1 855/4885POLB 3888/4885 |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | FGFR4, FGFR1, FGFR2 | KDM4E 1217/4885ALDH1A1 855/4885POLB 3888/4885 |
| US-12344611-B2 | Bridged cycloformylpyridine derivatives and uses thereof | FGFR4, FGFR1, FGFR3 | KDM4E 1213/4885ALDH1A1 1208/4885POLB 1151/4885 |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | FGFR4, FGFR1, FGFR3 | KDM4E 1213/4885ALDH1A1 1208/4885POLB 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.